Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rangering i aksjer #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aksjekurs
$0.00047446
Markedsverdi
$82.80
Endring (1 dag)
0.00%
Endring (1 år)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Kategori

Aksjeprishistorikk for Neovacs S.A. (ALNEV)
Høyeste sluttskurs: $0.00 den 2026-04-01

Laveste sluttskurs: $55.15K den 2010-04-01
Aksjeprishistorikk for Neovacs S.A. fra 2010 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) 0.00%
2025 -99.78%
2024 592,903.23%
2023 -96.32%
2022 -99.92%
2021 -98.03%
2020 -37.62%
2019 -71.75%
2018 -62.61%
2017 -24.49%
2016 -11.42%
2015 -67.56%
2014 9.35%
2013 -13.08%
2012 -30.76%
2011 40.12%
2010 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$40.81 -35.10%
DK
$441.70 -9.09%
US
$753.93 37.26%
US
$309.47 96.82%
BE
$840.87 43.10%
NL